Alex Richter

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

William T. Harvey, Scott M Elliott, Robert M. Davies, 2022, Nature Microbiology.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Joshua B. Singer, David A. Drew, Scott M Elliott, 2021, The Lancet. Public health.

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

J. A. Guerra-Assunção, K. Hood, B. Jani, 2024, Nature communications.

T cell immune memory after covid-19 and vaccination

L. Turtle, S. Dunachie, R. Payne, 2023, BMJ medicine.

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

J. Satsangi, P. Klenerman, S. Rowland-Jones, 2023, Nature Medicine.

COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

Scott M Elliott, Kevin R. Cole, Robert M. Davies, 2022, Scientific Reports.